Given the high morbidity and mortality of cardiovascular diseases (CVDs), novel biomarkers
for platelet reactivity are urgently needed. Ischemic events in CVDs are causally linked to …

Clopidogrel is increasingly being used for the secondary prevention of ischemic stroke
according to the updated guidelines on acute stroke management. Failure to achieve a drug …

Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to
clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence …

Aspirin resistance (AR) is a pressing problem in current ischemic stroke care. Although the
role of genetic variations is widely considered, the data still remain controversial. Our aim …

Objectives To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in
patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and …

Objective Conflicting data exist on the safety and efficacy of IV thrombolysis (IVT) in patients
with acute ischemic stroke (AIS) receiving dual antiplatelet pretreatment (DAPP). The aim of …

Aspirin, an antiplatelet drug, is commonly used at low doses for numerous indications,
including prophylaxis of cardiovascular, neurovascular, and venous thromboembolic events …

Background The prevalence of ex vivo 'high on-treatment platelet reactivity (HTPR)'and its
relationship with recurrent vascular events/outcomes in patients with ischaemic …

Background The optimal antithrombotic (antiplatelet or anticoagulant) treatment of patients
undergoing extracranial carotid artery interventions is a subject of debate. The aim of this …

Although coronary thrombosis (CT) is integral to cardiovascular outcomes, the underlying
pathophysiological mechanisms remain unclear. CT may occur in case of atherosclerotic …